These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9255691)

  • 1. ICD-antiarrhythmic drug and ICD-pacemaker interactions.
    Brode SE; Schwartzman D; Callans DJ; Gottlieb CD; Marchlinski FE
    J Cardiovasc Electrophysiol; 1997 Jul; 8(7):830-42. PubMed ID: 9255691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy.
    Greene HL
    Am J Cardiol; 1996 Aug; 78(4A):61-6. PubMed ID: 8780330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implanted automatic defibrillators: effects of drugs and pacemakers.
    Singer I; Guarnieri T; Kupersmith J
    Pacing Clin Electrophysiol; 1988 Dec; 11(12):2250-62. PubMed ID: 2463613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.
    Krol RB; Saksena S; Prakash A
    Curr Cardiol Rep; 1999 Nov; 1(4):282-8. PubMed ID: 10980855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combined transvenous implantation of cardioverter defibrillators and permanent pacemakers.
    Mattke S; Markewitz A; Müller D; Grünewald A; Fiek M; Schmöckel M; Hoffmann E; Steinbeck G
    Pacing Clin Electrophysiol; 1997 Nov; 20(11):2775-82. PubMed ID: 9392808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions.
    Marchlinski FE; Zado ES; Deely MP; Saligan J; Ashar M; Nayak H
    Am J Cardiol; 1999 Nov; 84(9A):69R-75R. PubMed ID: 10568663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].
    Tanner H; Hindricks G; Kottkamp H
    Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S; Murawski MM
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining antiarrhythmic drugs and implantable devices therapy: benefits and outcome.
    Santini M; Pandozi C; Ricci R
    J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():65-8. PubMed ID: 10590491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for antiarrhythmic drugs in patients with implantable defibrillators?
    Ho A; Assadi R; Pai SM; Pai RG
    Curr Cardiol Rep; 2006 Sep; 8(5):365-9. PubMed ID: 16956452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.
    Bunch TJ; Anderson JL
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):89-100. PubMed ID: 24288157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oversensing during ventricular pacing in patients with a third-generation implantable cardioverter-defibrillator.
    Kelly PA; Mann DE; Damle RS; Reiter MJ
    J Am Coll Cardiol; 1994 Jun; 23(7):1531-4. PubMed ID: 8195509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of drugs on defibrillation capacity.
    Dopp AL; Miller JM; Tisdale JE
    Drugs; 2008; 68(5):607-30. PubMed ID: 18370441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic Drug Therapy to Avoid Implantable Cardioverter Defibrillator Shocks.
    Abboud J; R Ehrlich J
    Arrhythm Electrophysiol Rev; 2016 Aug; 5(2):117-21. PubMed ID: 27617090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetected ventricular fibrillation in transvenous implantable cardioverter-defibrillators. Prospective comparison of different lead system-device combinations.
    Natale A; Sra J; Axtell K; Akhtar M; Newby K; Kent V; Geiger MJ; Brandon MJ; Kearney MM; Pacifico A
    Circulation; 1996 Jan; 93(1):91-8. PubMed ID: 8616948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations and late complications of third-generation automatic cardioverter-defibrillators.
    Nunain SO; Roelke M; Trouton T; Osswald S; Kim YH; Sosa-Suarez G; Brooks DR; McGovern B; Guy M; Torchiana DF
    Circulation; 1995 Apr; 91(8):2204-13. PubMed ID: 7697850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.